TR200602095T2 - Hümanize Anti-LT-Beta-R antikorları - Google Patents

Hümanize Anti-LT-Beta-R antikorları

Info

Publication number
TR200602095T2
TR200602095T2 TR2006/02095T TR200602095T TR200602095T2 TR 200602095 T2 TR200602095 T2 TR 200602095T2 TR 2006/02095 T TR2006/02095 T TR 2006/02095T TR 200602095 T TR200602095 T TR 200602095T TR 200602095 T2 TR200602095 T2 TR 200602095T2
Authority
TR
Turkey
Prior art keywords
beta
antibodies
humanized anti
humanized
humanized antibodies
Prior art date
Application number
TR2006/02095T
Other languages
English (en)
Inventor
Gardber Ellen
W. Saldanha Jose
Lyne Paul
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of TR200602095T2 publication Critical patent/TR200602095T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LT-Beta-R'ye insancıllaştırılmış antikorlar ve bunların kullanım metodu sağlanmıştır.
TR2006/02095T 2000-10-13 2001-10-12 Hümanize Anti-LT-Beta-R antikorları TR200602095T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24028500P 2000-10-13 2000-10-13
US27528901P 2001-03-13 2001-03-13
US29998701P 2001-06-21 2001-06-21

Publications (1)

Publication Number Publication Date
TR200602095T2 true TR200602095T2 (tr) 2007-02-21

Family

ID=27399340

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2003/00478T TR200300478T2 (tr) 2000-10-13 2001-10-12 Hümanize antiLT-ß-R antikorları
TR2006/02095T TR200602095T2 (tr) 2000-10-13 2001-10-12 Hümanize Anti-LT-Beta-R antikorları

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2003/00478T TR200300478T2 (tr) 2000-10-13 2001-10-12 Hümanize antiLT-ß-R antikorları

Country Status (25)

Country Link
US (2) US7429644B2 (tr)
EP (1) EP1326897A2 (tr)
JP (1) JP2004532608A (tr)
KR (1) KR20030041164A (tr)
CN (1) CN1547590A (tr)
AR (1) AR035352A1 (tr)
AU (2) AU1174702A (tr)
BG (1) BG107802A (tr)
BR (1) BR0114646A (tr)
CA (1) CA2425809A1 (tr)
CZ (1) CZ20031307A3 (tr)
EA (1) EA006945B1 (tr)
EE (1) EE200300179A (tr)
GE (1) GEP20063752B (tr)
HU (1) HUP0302573A2 (tr)
IL (1) IL155340A0 (tr)
IS (1) IS6779A (tr)
MX (1) MXPA03003144A (tr)
NO (1) NO20031642L (tr)
NZ (1) NZ525793A (tr)
PL (1) PL366307A1 (tr)
SK (1) SK5672003A3 (tr)
TR (2) TR200300478T2 (tr)
WO (1) WO2002030986A2 (tr)
YU (1) YU28503A (tr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
EP1539793A4 (en) * 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
RS20050481A (sr) * 2002-12-20 2007-08-03 Biogen Idec Ma Inc., Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
BRPI0509201A (pt) * 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
US8153123B2 (en) * 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
JP2007295524A (ja) * 2006-03-28 2007-11-08 Denso Corp 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム
AU2007267213B2 (en) * 2006-05-25 2012-03-29 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
NZ576032A (en) * 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
SG178002A1 (en) * 2006-10-20 2012-02-28 Biogen Idec Inc Treatment of demyelinating disorders
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
PL2907827T3 (pl) 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
DK2158315T3 (en) 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
EP3215528B1 (en) 2014-11-06 2019-08-07 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
EA201890297A1 (ru) * 2015-07-14 2018-06-29 Иммьюнекст, Инк. Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека
HK1257422A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 抗-因子d抗体变体缀合物及其用途
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
AU2020401755A1 (en) 2019-12-11 2022-08-04 Cilag Gmbh International Multispecific binding molecules comprising LTBR and EDB binding domains and uses thereof
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
CN115594759B (zh) * 2021-07-08 2026-04-24 洛阳普泰生物技术有限公司 犬轮状病毒单克隆抗体对及其应用
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
EP4688857A1 (en) 2023-04-07 2026-02-11 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a lymphotoxin beta receptor agonist
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025221736A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2157889T3 (es) 1990-06-27 2001-09-01 Biogen Inc Linfotoxina complejada de superficie.
AU692146B2 (en) 1990-06-27 1998-06-04 Biogen Idec Ma Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1996022788A1 (en) * 1995-01-26 1996-08-01 Biogen, Inc. LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CZ301026B6 (cs) 1998-01-30 2009-10-14 Biogen Idec Ma Inc. Použití kompozice inhibující interakci LT-ß a jeho receptoru pro výrobu prípravku k lécení folikulárního lymfomu
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP1539793A4 (en) 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
WO2004058191A2 (en) 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
RS20050481A (sr) 2002-12-20 2007-08-03 Biogen Idec Ma Inc., Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima

Also Published As

Publication number Publication date
EE200300179A (et) 2003-08-15
IS6779A (is) 2003-04-11
TR200300478T2 (tr) 2004-10-21
GEP20063752B (en) 2006-02-27
BR0114646A (pt) 2006-02-21
NO20031642L (no) 2003-06-13
SK5672003A3 (en) 2003-10-07
US20040058394A1 (en) 2004-03-25
PL366307A1 (en) 2005-01-24
WO2002030986A3 (en) 2003-03-13
CZ20031307A3 (cs) 2003-10-15
EA006945B1 (ru) 2006-06-30
AR035352A1 (es) 2004-05-12
US7429644B2 (en) 2008-09-30
WO2002030986A2 (en) 2002-04-18
CA2425809A1 (en) 2002-04-18
YU28503A (sh) 2006-05-25
US20090092601A1 (en) 2009-04-09
MXPA03003144A (es) 2004-12-06
EA200300464A1 (ru) 2003-10-30
AU1174702A (en) 2002-04-22
BG107802A (bg) 2004-01-30
AU2002211747B2 (en) 2007-11-29
NZ525793A (en) 2008-04-30
KR20030041164A (ko) 2003-05-23
JP2004532608A (ja) 2004-10-28
NO20031642D0 (no) 2003-04-10
HUP0302573A2 (hu) 2003-10-28
CN1547590A (zh) 2004-11-17
IL155340A0 (en) 2003-11-23
EP1326897A2 (en) 2003-07-16

Similar Documents

Publication Publication Date Title
TR200300478T2 (tr) Hümanize antiLT-ß-R antikorları
CY2019029I1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DE60010098D1 (de) 28-epirapaloge
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
EP1071458A4 (en) HUMANIZED ANTIBODIES AND CORRESPONDING USES THEREOF
EP1572077A4 (en) USES OF MONOCLONAL ANTIBODY 8H9
EE200000642A (et) Suurendatud saagisega FAPalfa-spetsiifilised antikehad
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
ID25792A (id) Antibodi-antibodi terhadap cd40 manusia
EE201200006A (et) CTLA-4 vastased inimese monoklonaalsed antikehad
ITMI20011986A0 (it) Metodo e composizione per l'attivazione di cellule presentanti l'antigene
CY2014038I1 (el) Αντι-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
EA200201214A1 (ru) Замещенные тиоацетамиды
DE60140516D1 (de) Behandlung von fluorkohlenstoff- ausgangsmaterialien
NO20032542L (no) Dempede anti-CD28-antistoffer og anvendelse derav
NO20031860D0 (no) Kahalaolid F
EP1267930A4 (en) CROSS-REACTION DISPLACEMENT ANTIBODIES FROM COLLAGEN BINDING PROTEINS AND METHOD OF IDENTIFICATION AND USE
BR0015872A (pt) Agentes antitrombóticos
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
BR0110902A (pt) Inibidores de mmp-9/mmp-2
DE60139694D1 (de) Menschliche myelom zelllinie
MY133881A (en) "calcilytic compounds"
EP1272205A4 (en) SIALOADHESIN FACTOR-2 ANTIBODIES